News | April 28, 2022
Sanofi continues to deliver strong business
Business EPS of €1.94, up 20.5% on a reported basis and 16.1% at CER, also benefitting from an improved effective tax rate
Business EPS of €1.94, up 20.5% on a reported basis and 16.1% at CER, also benefitting from an improved effective tax rate
The round also saw participation from US-based fund 57 Stars, a few prominent angel investors, existing investors Stellaris Venture Partners, Vertex Ventures, and Alteria Capital
Aflibercept is the second biosimilar product that has entered the clinical trial phase after biosimilar Adalimumab
This recommendation is based on new data from two randomized controlled trials involving 3078 patients
The recombinant nanoparticle-based rabies G protein vaccine is prepared using virus-like particle technology.
Headwinds related to pricing pressures and rising raw material costs will result in some contraction in margins in Q4 FY22 and FY23
An integrated and agile approach enables the pharmaceutical CDMO industry to simplify manufacturing as it moves from primary care medicines to specialty medicines
Saransh Chaudhary, President, Global Critical Care Division, Venus Remedies and CEO, Venus Medicine Research Centre In conversation with Thomas C Thottathil, Editor, www.indianpharmapost.com identified key areas that the company is focusing on in its Mission 2025
To date, 30 crore vaccines have been produced as part of the commitment made to the Government of India
Price was the key driver for the period
Subscribe To Our Newsletter & Stay Updated
